國產(chǎn)水痘減毒活疫苗保護效果的系統(tǒng)評價和證據(jù)質(zhì)量初步分析
[Abstract]:Objective to evaluate and analyze the protective effect and evidence quality of live attenuated varicella vaccine (Varicella Attenuated Live Vaccine,Var V). Methods (The Cochrane Central Register of Controlled Trials), medical literature analysis and online retrieval system (Medline), (1915 ~) and Wanfang database (1988 ~) were used to search the medical literature of Cochrane controlled experimental center registry. Domestic Var V was targeted at children aged 13 years old. The protective effects of randomized controlled trials were included in the analysis, The data were extracted by two evaluators, the research quality and statistical analysis were carried out by Meta analysis software (Review Manager,Rev Man) version 5.2, and the quality of integrated evidence was rated by using the evaluation of evidence recommendation classification and (The Grading of Recommendations Assessment,Development and Evaluation;GRADE). Results A total of 6 original studies were included without heterogeneity. The intervention measures were freeze-dried (Freeze-dried) Var V, control measures were measles-mumps attenuated live vaccine). Most of them were children aged 3 to 6 years old. The research sites are respectively Shandong, Meta-analysis of Hunan and Hubei Province showed that inoculation with Vra V significantly reduced the probability of chickenpox incidence [relative risk (Relative Risk,RR) 0.1195% confidence interval (Confidence Interval,CI) 0.070.16]. The results were in agreement with other domestic and international studies. According to the GRADE evaluation method, the quality of the integrated evidence was "extremely low". Conclusion the results of this study are based on the published literature. The protective effect of Var V on the market in China may be different from the estimated value, suggesting that the research quality of domestic Var V and other evaluation studies in this field should be improved. And improve the quality and integrity of the article report.
【作者單位】: 中國疾病預(yù)防控制中心免疫規(guī)劃中心;北京大學(xué)中國衛(wèi)生發(fā)展研究中心;
【分類號】:R186
【參考文獻】
相關(guān)期刊論文 前10條
1 王連成,劉曄,李莉,李占春,李彥成,哈秀杰,徐秀鳳,閻素志,王文忠,南一范,周鐵群,王劍峰,邱平,李長貴;國產(chǎn)凍干水痘減毒活疫苗免疫效果觀察[J];華南預(yù)防醫(yī)學(xué);2003年02期
2 馬福寶;羅林云;張龍華;陳海平;封多佳;高君;郜曉智;付方;沈心亮;過琴媛;;凍干水痘減毒活疫苗現(xiàn)場流行病學(xué)效果研究(Ⅰ)[J];中國疫苗和免疫;2009年03期
3 宋立志;陳海平;沈心亮;肖作奎;羅林云;李明;張洪樣;呂靜靜;王菲;封多佳;徐愛強;過琴媛;;凍干水痘減毒活疫苗現(xiàn)場流行病學(xué)保護效果研究(Ⅱ)[J];中國疫苗和免疫;2011年01期
4 王志勇;肖奇友;李放軍;陳海平;宋繼萍;李振海;廖國樂;何德彪;陳斌;張寒麗;張淑君;黃銘華;李俊華;高立冬;;國產(chǎn)凍干水痘減毒活疫苗安全性和免疫效果研究[J];中國疫苗和免疫;2011年06期
5 李娜;方凱;馬淑玲;黃少平;尚鵬輝;;國內(nèi)水痘減毒活疫苗預(yù)防效果及其安全性的系統(tǒng)評價[J];中國疫苗和免疫;2012年01期
6 張遲;羅林云;葉建君;陳海平;徐順平;余林生;蔡碧;李書華;趙明江;付方;沈心亮;;凍干水痘減毒活疫苗現(xiàn)場流行病學(xué)保護效果研究(Ⅲ)[J];中國疫苗和免疫;2012年02期
7 周志娜,姚云梅,王桂玲;兒童接種水痘疫苗621例近期流行病學(xué)效果觀察[J];職業(yè)與健康;2004年06期
8 陳耀龍;李幼平;杜亮;王莉;文進;楊曉妍;;醫(yī)學(xué)研究中證據(jù)分級和推薦強度的演進[J];中國循證醫(yī)學(xué)雜志;2008年02期
9 Gordon Guyatt;Andrew D.Oxman;Elie Akl;Regina Kunz;Gunn Vist;Jan Brozek;Susan Norris;Yngve Falck-Ytter;Paul Glasziou;Hans deBeer;Roman Jaeschke;David Rind;Joerg Meerpohl;Philipp Dahm;Holger J.Schünemann;GRADE工作組;李幼平;楊曉妍;蔣蘭慧;沈建通;;GRADE指南:Ⅰ.導(dǎo)論——GRADE證據(jù)概要表和結(jié)果總結(jié)表[J];中國循證醫(yī)學(xué)雜志;2011年04期
10 Howard Balshem;Mark Helfanda;Holger J.Schunemann;Andrew D.Oxman;Regina Kunz;Jan Brozek;Gunn E.Vist;Yngve Falck-Ytter;Joerg Meerpohl;Susan Norris;Gordon H.Guyatt;GRADE工作組;李幼平;楊曉妍;高,
本文編號:2244495
本文鏈接:http://sikaile.net/yixuelunwen/yufangyixuelunwen/2244495.html